Why Cancer Vaccines' Greatest Advantage May Be Durability of Response, Not Immediate Tumor Shrinkage
Cellex Life CEO Dr Eric von Hofe and Professor of Immunology at Mayo Clinic, Dr Keith L. Knutson, explain why individualized tumor profiling, not off-the-shelf targeting, is key to effective personalized cancer vaccines.